FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

1. ARGX stock declines 6.56% after FDA safety concerns for Vyvgart Hytrulo. 2. FDA identifies severe risks associated with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment. 3. European Commission approves Vyvgart for CIDP, offering new treatment options. 4. No analysts have bearish ratings; average 1-year price target at $753.23. 5. Guggenheim sets street high target at $1065; Baird’s low target is $680.